Erlotinib Terminated Phase 1 Trials for Brain and Central Nervous System Tumors Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00227032Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme